IDT Australia Limited (AU:IDT) has released an update.
IDT Australia Limited is set to enhance the pharmaceutical landscape by establishing the nation’s first commercial Antibody-Drug-Conjugate (ADC) manufacturing facility, with a $3.8 million grant from the Victorian Government. This new facility is poised to strengthen IDT’s position in high potency and containment manufacturing, while propelling the growth of its Advanced Therapies business. The move aligns with global market trends, as ADCs are expected to significantly disrupt the traditional chemotherapy market and reach a valuation of US$140 billion in the next 15 years.
For further insights into AU:IDT stock, check out TipRanks’ Stock Analysis page.
